SCHEMBL26917043

SCHEMBL26917043

Cn1ccc(-c2cc(B(O)O)cnc2N)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.41
▸ PIK3CB P42338 2/20 0.41
▸ PIK3CG P48736 2/20 0.41
▸ IKBKE Q14164 1/20 0.39
▸ TBK1 Q9UHD2 1/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ PDGFRB P09619 3/20 0.38
▸ KDR P35968 3/20 0.38
▸ BMPR1A P36894 1/20 0.37
▸ ACVRL1 P37023 1/20 0.37
▸ ACVR1 Q04771 1/20 0.37
▸ PIP5K1C O60331 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PI4KA P42356 1/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36
▸ FGFR1 P11362 2/20 0.35
▸ FGFR2 P21802 2/20 0.35
▸ FGFR3 P22607 2/20 0.35
▸ JMJD6 Q6NYC1 2/20 0.35
▸ LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19480882 0.81 CYP2A6 (0.46) PIK3CDPIK3CBPIK3CGIKBKETBK1
SCHEMBL26916829 0.77 KMT2A (0.43) PIK3CDPIK3CBPIK3CGIKBKETBK1
SCHEMBL19480880 0.77 ATR (0.42) PIK3CDPIK3CBPIK3CGIKBKETBK1
SCHEMBL29857640 0.77 KMT2A (0.43) PIK3CDPIK3CBPIK3CGIKBKETBK1
SCHEMBL25255498 0.73 LRRK2 (0.57) PIK3CDPIK3CBPIK3CGIKBKETBK1
SCHEMBL30177024 0.71 PIK3CD (0.42) PIK3CDPIK3CBPIK3CGIKBKETBK1
SCHEMBL28983677 0.71 PIK3CD (0.42) PIK3CDPIK3CBPIK3CGIKBKETBK1
SCHEMBL26916304 0.71 MAP3K12 (0.48) —
SCHEMBL19480883 0.71 KEAP1 (0.46) KEAP1BMPR1AACVRL1ACVR1JMJD6
SCHEMBL25225852 0.71 MKNK1 (0.52) PIK3CDPIK3CBPIK3CGIKBKETBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174683-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-05-30 — — US disclosed
EP-4288437-A1 MAP4K1 INHIBITORS Bayer Aktiengesellschaft (DE) 2023-12-13 — — EP disclosed
WO-2022167627-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2022-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174683-A1 MAP4K1 INHIBITORS MAP3K4, MAP4K4, MAP4K1 PIK3CD 1103/4885PIK3CB 1188/4885PIK3CG 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback